At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 251 enrolled
Drug / intervention
Liraglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity. 56-week, Double-blind, Randomised, Parallel-group, Placebo-controlled Multi-national Trial Followed by a 26-week Period Off Study-drug
In Brief
A Phase 3 clinical trial evaluating Liraglutide and Placebo for Metabolism and Nutrition Disorder and Obesity. Completed, enrolled 251 participants across 33 sites in 5 countries.
Detailed Summary
This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in pubertal adolescent subjects with obesity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolism and Nutrition Disorder, Obesity
CountriesBelgium, Mexico, Russia, Sweden, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartSep 2016
Primary CompletionFeb 2019
Study CompletionAug 2019
TodayJul 2026
First PostedSep 28, 2016
Enrollment StartSep 29, 2016
Primary CompletionFeb 14, 2019
Study CompletionAug 8, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.8 years ago
Interventions
Liraglutidedrug
Administered once daily subcutaneously (s.c., under the skin)
Placebodrug
Administered once daily subcutaneously (s.c., under the skin)